AAAAAA
Results:
1-16
|
Results: 16
Authors:
Brunswick, DJ
Amsterdam, JD
Fawcett, J
Quitkin, FM
Reimherr, FW
Rosenbaum, JF
Beasley, CM
Citation: Dj. Brunswick et al., Fluoxetine and norfluoxetine plasma levels after discontinuing fluoxetine therapy, J CL PSYCH, 21(6), 2001, pp. 616-618
Authors:
Czekalla, J
Beasley, CM
Dellva, MA
Berg, PH
Grundy, S
Citation: J. Czekalla et al., Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis, J CLIN PSY, 62(3), 2001, pp. 191-198
Authors:
Czekalla, J
Kollack-Walker, S
Beasley, CM
Citation: J. Czekalla et al., Cardiac safety parameters of olanzapine: Comparison with other atypical and typical antipsychotics, J CLIN PSY, 62, 2001, pp. 35-40
Authors:
McGrath, PJ
Stewart, JW
Petkova, E
Quitkin, FM
Amsterdam, JD
Fawcett, J
Reimherr, FW
Rosenbaum, JF
Beasley, CM
Citation: Pj. Mcgrath et al., Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression, J CLIN PSY, 61(7), 2000, pp. 518-524
Authors:
Beasley, CM
Nilsson, ME
Koke, SC
Gonzales, JS
Citation: Cm. Beasley et al., Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: A meta-analysis of the 20-mg/day dose, J CLIN PSY, 61(10), 2000, pp. 722-728
Authors:
Beasley, CM
Koke, SC
Nilsson, ME
Gonzales, JS
Citation: Cm. Beasley et al., Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: An updated meta-analysis, CLIN THER, 22(11), 2000, pp. 1319
Authors:
Revicki, DA
Genduso, LA
Hamilton, SH
Ganoczy, D
Beasley, CM
Citation: Da. Revicki et al., Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: Quality of life and clinical outcomes of a randomized clinical trial, QUAL LIFE R, 8(5), 1999, pp. 417-426
Authors:
Hudson, MF
Beasley, CM
Benedict, RH
Carlson, JR
Craig, BF
Mason, SC
Citation: Mf. Hudson et al., Elder abuse - Some African American views, J INTERP V, 14(9), 1999, pp. 915-939
Authors:
Callaghan, JT
Bergstrom, RF
Ptak, LR
Beasley, CM
Citation: Jt. Callaghan et al., Olanzapine - Pharmacokinetic and pharmacodynamic profile, CLIN PHARMA, 37(3), 1999, pp. 177-193
Authors:
Perry, PJ
Sanger, T
Beasley, CM
Citation: Pj. Perry et al., Plasma olanzapine and clinical response: Reply, J CL PSYCH, 19(2), 1999, pp. 193-194
Authors:
Zajecka, J
Amsterdam, JD
Quitkin, FM
Reimherr, FW
Rosenbaum, JF
Tamura, RN
Sundell, KL
Michelson, D
Beasley, CM
Citation: J. Zajecka et al., Changes in adverse events reported by patients during 6 months of fluoxetine therapy, J CLIN PSY, 60(6), 1999, pp. 389-394
Authors:
Beasley, CM
Citation: Cm. Beasley, Olanzapine and tardive dyskinesia - Author's reply, BR J PSYCHI, 175, 1999, pp. 392-392
Authors:
Tran, PV
Tollefson, GD
Sanger, TM
Lu, YL
Berg, PH
Beasley, CM
Citation: Pv. Tran et al., Olanzapine versus haloperidol in the treatment of schizoaffective disorder- Acute and long-term therapy, BR J PSYCHI, 174, 1999, pp. 15-22
Authors:
Beasley, CM
Dellva, MA
Tamura, RN
Morgenstern, H
Glazer, WM
Ferguson, K
Tollefson, GD
Citation: Cm. Beasley et al., Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol, BR J PSYCHI, 174, 1999, pp. 23-30
Authors:
Beasley, CM
Citation: Cm. Beasley, Response to letter of Professor Tim Lambert, AUST NZ J P, 33(1), 1999, pp. 121-122
Authors:
Michelson, D
Amsterdam, JD
Quitkin, FM
Reimherr, FW
Rosenbaum, JF
Zajecka, J
Sundell, KL
Kim, Y
Beasley, CM
Citation: D. Michelson et al., Changes in weight during a 1-year trial of fluoxetine, AM J PSYCHI, 156(8), 1999, pp. 1170-1176
Risultati:
1-16
|